UOC
VKTX icon

UBS O'Connor’s Viking Therapeutics VKTX Stock Holding History

UBS O'Connor’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,316
Closed -$645K – 580
2024
Q3 		$716K Buy
+11,316
New +$664K 0.02% 313
2024
Q1 		– Sell
-22,141
Closed -$985K – 603
2023
Q4 		$412K Sell
22,141
-35,764
-62% -$468K 0.01% 370
2023
Q3 		$641K Buy
57,905
+16,000
+38% +$229K 0.01% 372
2023
Q2 		$679K Sell
41,905
-23,703
-36% -$497K 0.01% 418
2023
Q1 		$1.09M Buy
+65,608
New +$678K 0.03% 393
2022
Q4 		– Sell
-247,000
Closed -$672K – 322
2022
Q3 		$672K Buy
+247,000
New +$809K 0.01% 787
2019
Q1 		– Sell
-102,842
Closed -$787K – 144
2018
Q4 		$787K Buy
102,842
+7,842
+8% +$93.8K 0.03% 178
2018
Q3 		$1.66M Buy
+95,000
New +$1.13M 0.04% 181

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS O'Connor's VKTX Position: Q4 2024 in Review

UBS O'Connor sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 11,316 shares — an estimated $645K sold.

UBS O'Connor first reported a position in VKTX in Q3 2018 and held it in 8 quarters. The position peaked at $1.66M in Q3 2018. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • UBS O'Connor reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • UBS O'Connor sold 11,316 Viking Therapeutics shares in Q4 2024, an estimated $645K.
  • UBS O'Connor first reported a position in Viking Therapeutics in Q3 2018 and held it in 8 quarters.
  • UBS O'Connor's Viking Therapeutics position peaked at $1.66M in Q3 2018.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.